Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $668,625.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 12,500 shares of the stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $53.49, for a total transaction of $668,625.00. Following the completion of the sale, the insider now owns 169,721 shares in the company, valued at approximately $9,078,376.29. This trade represents a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Timothy Rolph also recently made the following trade(s):

• On Friday, June 6th, Timothy Rolph sold 25,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $55.04, for a total value of $1,376,000.00.
• On Tuesday, May 6th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $43.43, for a total value of $542,875.00.
• On Thursday, April 24th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $41.03, for a total value of $256,437.50.
• On Monday, April 7th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $35.88, for a total value of $224,250.00.

Akero Therapeutics Trading Down 2.9%

NASDAQ AKRO opened at $52.96 on Thursday. The stock has a market capitalization of $4.22 billion, a price-to-earnings ratio of -14.12 and a beta of -0.16. The stock’s 50 day moving average price is $43.18 and its two-hundred day moving average price is $39.98. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics, Inc. has a 52 week low of $21.02 and a 52 week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of ($1.01) by $1.91. As a group, analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. raised its stake in shares of Akero Therapeutics by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,787 shares of the company’s stock worth $72,000 after purchasing an additional 321 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Akero Therapeutics by 14.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,664 shares of the company’s stock worth $114,000 after purchasing an additional 338 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Akero Therapeutics by 30.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company’s stock worth $67,000 after purchasing an additional 390 shares in the last quarter. Amalgamated Bank raised its stake in shares of Akero Therapeutics by 19.0% during the 1st quarter. Amalgamated Bank now owns 2,570 shares of the company’s stock worth $104,000 after purchasing an additional 410 shares in the last quarter. Finally, Summit Investment Advisors Inc. raised its stake in shares of Akero Therapeutics by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock worth $197,000 after purchasing an additional 450 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on AKRO. Citigroup decreased their price objective on Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. Bank of America boosted their price objective on Akero Therapeutics from $63.00 to $64.00 and gave the company a “buy” rating in a research report on Tuesday, May 27th. Morgan Stanley reiterated an “overweight” rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Finally, HC Wainwright boosted their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $82.50.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.